Expanded use of the TAXUS express stent: Two-year safety insights from the 7,500 patient ARRIVE registry programme

John M. Lasala, David A. Cox, Stephen J. Lewis, Peter N. Tadros, Robert C. Haas, Marc J. Schweiger, Anil Chhabra, William J. Untereker, Ruth M. Starzyk, Stephen R. Mascioli, Keith D. Dawkins, Donald S. Baim

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Aims: We report 2-year outcomes in a large unselected drug-eluting stent population (N=7,492) in the TAXUS Express2 ARRIVE post-market surveillance programme (101 U.S. sites). Methods and results: No specific inclusion/exclusion criteria were mandated; patients enrolled at procedure initiation. Two-year follow-up was 94%, with independent adjudication of major cardiac events, monitoring of patients with cardiac events and an additional 10-20% sample by site. Most ARRIVE cases (64%, n=4,794) typified expanded use based on patient/lesion characteristics outside the simple use (single vessel/stent) pivotal trial populations. These expanded use patients had higher 2-year rates than simple use patients for mortality (7.8% vs. 4.2%, P<0.001), myocardial infarction (MI, 3.9% vs. 2.2%, P<0.001), target lesion revascularisation (TLR, 9.2% vs. 5.4%, P<0.001), and stent thrombosis (3.3% vs. 1.4%, P<0.001). Among subgroups with renal disease, chronic total occlusion (CTO), lesion >28 mm, reference vessel diameter (RVD) <2.5 mm, multivessel stenting, acute MI, bifurcation, vein graft, or in-stent restenosis, TLR ranged from 3.8% to 8.9% in year one, and from 1.3% to 6.0% during year two. Conclusions: Mortality and stent-related events were higher in expanded use than simple use patients in the pivotal trials. ARRIVE provides a detailed estimate of procedural and 2-year outcomes in such real-world patients.

Original languageEnglish
Pages (from-to)67-77
Number of pages11
Issue number1
StatePublished - 2009


  • Coronary disease
  • Expanded use of drug-eluting stents
  • Registries
  • Restenosis
  • Stents


Dive into the research topics of 'Expanded use of the TAXUS express stent: Two-year safety insights from the 7,500 patient ARRIVE registry programme'. Together they form a unique fingerprint.

Cite this